Cargando…
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature
BACKGROUND: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%–90% of these cancers. S...
Autores principales: | Norum, Jan, Nieder, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173248/ https://www.ncbi.nlm.nih.gov/pubmed/30305940 http://dx.doi.org/10.1136/esmoopen-2018-000406 |
Ejemplares similares
-
Tobacco smoking and smoking cessation in times of COVID-19
por: Elling, Jan M., et al.
Publicado: (2020) -
Sami-speaking municipalities and a control group's access to somatic specialist health care (SHC): a retrospective study on general practitioners’ referrals
por: Norum, Jan, et al.
Publicado: (2012) -
Socioeconomic characteristics and health outcomes in Sami speaking municipalities and a control group in northern Norway
por: Norum, Jan, et al.
Publicado: (2012) -
Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2023) -
Scientific Evidence for the Addictiveness of Tobacco and Smoking Cessation in Tobacco Litigation
por: Roh, Sungwon
Publicado: (2018)